|
It has been known
for some years now that diabetic subjects find it more difficult to lose
weight than non-diabetic subjects (Wing RR, 1987; Norris SL, 2004; Hensrud
DD, 2001; Campbell L, 2001), largely due to the metabolic disturbances
associated with their disease. Therefore, it is not surprising that the type
2 diabetic population of RIO Diabetes have lost slightly less weight than the
non-diabetic population of other RIO trials. In addition, it is notoriously
difficult to achieve any significant weight loss in patients who are on an
antidiabetic drug. In this difficult population of metformin- or
sulphonylurea-treated diabetics in the RIO Diabetes study, a significant
weight loss of 3.9 kg net of placebo was achieved. The average weight loss in
the rimonabant 20 mg group of the RIO Diabetes study was 5.3 kg, vs. 1.4 kg
for placebo (p<0.001 vs placebo, ITT LOCF). For those patients who
completed the study, the mean weight loss was 6.1 kg compared to 1.9 kg for
placebo (p<0.001).
|